CrownBio Demonstrates Scientific Advancements in Metabolic Disease with a validated and improved translatable model for obesity and Type 2 Diabetes drug discovery
(Santa Clara, Calif., July 6, 2017) — Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, cardiovascular and metabolic disease research, announces the publication of two new scientific papers indicating that the FATZO model is a significantly improved rodent model for obesity, dysmetabolism and type 2 diabetes for pre-clinical studies.
The research conducted by CrownBio, and collaborators was published 06/22/17 in two PLOS ONE papers.
Glucose dysregulation and response to common anti-diabetic agents in the FATZO/Pco mouseCorrelation of disease severity with body weight and high fat diet in the FATZO/Pco mouse
Charles Van Jackson, CSO CrownBio Indiana commented, “The FATZO mouse is an improved translatable model that provides us with a better understanding of the physiological and cellular mechanisms that lead from obesity, metabolic disorders, to diabetes. The data presented in these papers demonstrates that FATZO has several advantages over traditional rodent models and will impact the speed of drug discovery”
The FATZO model, has been developed to provide polygenic obesity and a metabolic pattern of hyperglycemia and hyperinsulinemia. These studies demonstrate that the FATZO model is a more translatable rodent model for obesity and type 2 diabetes, including for the development of anti-diabetic therapeutics.
“The publication of these papers are indicative of how CrownBio continues to further validate the translatability of this model and our commitment to bring to the market novel models that are more representative of human conditions of obesity and type 2 diabetes.” said Laurie Heilmann, SVP of Global Strategy, Marketing & Business Development. “These scientific advancements of translatable model development are the key to early discovery of disease and enable faster drug discovery.”
For more information on CrownBio’s commitment to furthering the field of cardiovascular and metabolic drug discovery, visit https://www.crownbio.com/cvmd
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Contact details
-
- Louise Stenson
-
Crown Bioscience Company Inquiries
Communications Manager - louise.stenson@crownbio.com
Related topics
Related news
Crown Bioscience Wins 2024 Fierce CRO Award for Excellence in Client Service and Partnership
Crown Bioscience wins 2024 Fierce CRO Award for excellence in client service, underscoring its commitment to innovative drug development partnerships.
Crown Bioscience Wins BioTech Breakthrough Award for Drug Development Innovation
Crown Bioscience's OrganoidXplore receives BioTech Award, revolutionizing oncology with advanced preclinical screening.
Prostate Cancer Breakthrough: Crown Bioscience Collaborates in €1.75M Eurostars Funded Project for Novel Liquid Biops...
Crown Bioscience, part of JSR Life Sciences, joins a €1.75M Eurostars project to develop a novel liquid biopsy for prostate cancer, enhancing treatment.
Crown Bioscience Expands Singapore Facility with Advanced Oncology Models and Imaging Capabilities
Crown Bioscience enhances its global presence with the expansion of its Singapore facility, featuring cutting-edge oncology models and imaging capabilities.
Crown Bioscience Partners with CTI to Support Consulting Services in Oncology Drug Development
Crown Bioscience announces a strategic partnership with Clinical Trial & Consulting Services (CTI), a renowned global full-spectrum research service provider, to bolster oncology-focused consulting...